不同药物剂量对脑梗死康复期病人缺血性卒中再发对比分析的预防  

Analyses of controlled trial of prevention against ischemic stroke with different agents and dosege for patients recovering from cerebral infarction(CI)

作　　者：朱力山[1] 丁进芳[1] 边军[1] 席惠群[1] 张琼[1] 

机构地区：[1]甘肃省人民医院,兰州甘肃730000

出　　处：《现代康复》2001年第1期55-56,共2页Modern Rehabilitation

摘　　要：目的 探讨蚓激酶 Lum，抵可力得 (TIC)及三种剂量的阿斯匹林 (ASA)对康复期脑梗死病人缺血性卒中再发的预防作用。方法 对已患过脑梗死的病人 165例，随机分为 5组应用 ASA25mg/d、 50mg/d、 100mg/d、 TIC、 Lum进行缺血性卒中再发的预防性治疗。结果 与 ASA25mg/d组的每 100例月累积复发率 (7.75％ )相比， ASA 50mg/d(6.25％ ),相对危险性减少 20％ (RR I.25;95％ CI,0.73－ 1.25);ASA 100mg 12组 (4.75％ )， (RR1.70;95％ CL， 0.69～ 2.26);Lum 600mg/d组 (3.78％ )，相对危险减少 51.2％ (RR2.05;95％ CI， 1.1～ 3.80);TIC 250mg/d组相对危险性减少 41％； (3.52％ )，相对危险性减少 54.6％ (RR2.20;95％ CI,1.1～ 21.3)。结论 TIC250mg/d作为二级预防最为有效，除了传统的抗血小板剂外， Lum 600mg/d也可用作缺血性卒中的二级预防。Objective To compare different effects of prevention against recurrence of ischemic stroke in patients recovering from CI with Ticlopidine(TIC).Lumbrokinase(Lum)and Aspirin(ASA)in three doseges.Method 165patients,who had undergone cerebral infarction were randomized among 5 groups based on different agents and dosage used for prevention against recurrence of ischemic stroke.They were group ASA 25mg/d， 35cases;group ASA 50mg/d,33； group ASA 100mg/d,34group TIC 250mg/d， 31and group Lum 600mg/d,32.Result Cumulatyive Recurrence Rate10 2 month 1person 1(CRR)was 6.25％ in group ASA 50mg/d versus CRR 7.75％ in group 25mg/d,Reduction of Relative Risk (RRR)was 20％ (RR1.25;95％ CI,0.73－ 2.15);4.57％ in group ASA 100mg/d,RRR41％ (RR1.70;95％ CI,0.69－ 2.26);3.78％ in group Lum 600mg/d,RRR51.2％ (RR2.05;95％ CI,1.1－ 3.80)and 3.52％ in group TIC 250mg/d,RRR54.6％ (RR2.20;95％ CI,1.1－ 4.3).Conclusion The preliminary results have indicated that TIC 250mg/d is most effective agent of all and that in addition to conventional antiplatelet agents,Lumbrokinase 600mg/d can be used for secondany prevention of ischemic stroke.

关 键 词：二级预防 脑梗死 康复期 脑缺血 再发 药物剂量 

分 类 号：R743.330.9[医药卫生—神经病学与精神病学] R743.310.1[医药卫生—临床医学]